VICO Vicore Pharma Holding AB (publ)
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.…
Industry Peers
BiotechnologyKey Statistics
About Vicore Pharma Holding (STO: VICO)
›
Vicore Pharma Holding (STO: VICO) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 50 employees.
The shares were at 10.24 SEK on 19 November 2026, roughly unchanged over 52 weeks. Its 52-week range is 8.560 SEK to 18.24 SEK: the price is 43.9% below the high and 19.6% above the low.
Its market capitalisation is 2.88B SEK.
Vicore Pharma Holding reports return on equity of -43.6% and revenue down 21.8% year over year.
It holds more cash than debt, a net cash position of 771.99M SEK. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 26.50 SEK is 158.8% above the current price. The next earnings report is expected on 25 February 2027.